Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › URGN
SILVERARC CAPITAL MANAGEMENT, LLC position in URGN
UROGEN PHARMA LTD · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 1,148,689 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$46.7M, representing 5.95% of its reported portfolio and ranking #4 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's URGN position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in URGN in Q3 2023 at 508,883 shares (US$7.1M). The position peaked in Q2 2026 at 1,301,979 shares, worth US$47.9M. Across 13 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,148,689 shares valued at US$46.7M — a reduction of -153,290 shares quarter over quarter.. Notable position changes include a 117% increase in Q2 2024 (shares fell 24% over the following quarter), a 46% increase in Q2 2025 (shares rose 46% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 508.88K | $7.13M | New |
| Q4 2023 | 525.40K | $7.88M | Add |
| Q1 2024 | 508.59K | $7.63M | Reduce |
| Q2 2024 | 1.10M | $18.49M | Add |
| Q3 2024 | 901.13K | $11.44M | Reduce |
| Q4 2024 | 1.12M | $11.93M | Add |
| Q1 2025 | 1.38M | $15.28M | Add |
| Q2 2025 | 2.02M | $27.71M | Add |
| Q3 2025 | 1.58M | $31.47M | Reduce |
| Q4 2025 | 1.74M | $40.72M | Add |
| Q1 2026 | 1.50M | $27.02M | Reduce |
| Q2 2026 | 1.30M | $47.91M | Reduce |
| Q3 2026 | 1.15M | $46.67M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 44 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $89.37M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- NEXT CENTURY GROWTH INVESTORS LLC 297.08K sh · $12.07M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held URGN?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in URGN?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 1.15M shares of URGN (UROGEN PHARMA LTD), valued at $46.67M, representing 5.95% of its reported portfolio and ranking #4.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling URGN?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in URGN. The position peaked in Q2 2026 at 1.30M shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.